Microbiome–Gut–Brain Axis Modulation: New Approaches in Treatment of Neuropsychological and Gastrointestinal Functional Disorders
ACS Medicinal Chemistry Letters – May 11, 2023
Source: OpenAlex
Summary
Psychedelics like psilocybin and lysergic acid diethylamide (LSD) may offer novel approaches in medicine by influencing our gut microbiome. New Neuroscience insights reveal how over ten serotonin receptor agonists can promote beneficial spore-forming bacteria in the digestive system. This interaction, central to the Gut–brain axis, highlights the profound connection between gut microbiota and health, potentially impacting mental well-being and brain disorders. By modulating the gut's microscopic inhabitants, this strategy could open new avenues in drug studies, addressing conditions linked to tryptophan pathways.
Abstract
The gut-brain axis (GBA) refers to the sophisticated bidirectional communication system connecting the digestive system with the central nervous system. This interaction is enabled by a series of intricate signaling processes, encompassing various neuro-immune and hormonal pathways. The association between the gut microbiome and mental health has garnered immense scientific and public interest, driven by an enhanced understanding of the microbiome's role in facilitating communication between the gut and the brain. This Patent Highlight discloses methods for promoting the colonization of spore-forming bacteria in the gastrointestinal track. These methods include administering a serotonin receptor agonist, such as psilocybin, psilocin, N,N-dimethyltryptamine, bufotenine, 5-methoxy-N,N-dimethyltryptamine, lysergic acid diethylamide, ergine, mescaline, 3,4-methylenedioxyamphetamine, 2,5-dimethoxy-4-methylamphetamine, and others.